Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities

Running, not enrolling · Phase 2

Conditions studied: Proteinuric Kidney Disease

In brief

The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).

Key facts

Study ID
NCT06794996
Run by
Vertex Pharmaceuticals Incorporated
People needed
42
Starts
2025-02-04
Expected to finish
2026-12-30
Last updated by the study team
2026-05-05

Who can join

Age: 18 and older, up to 67. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.